Comparing midazolam to stop seizures when given through muscle versus when given through nose.
Not Applicable
- Conditions
- Health Condition 1: G00-G99- Diseases of the nervous systemHealth Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
- Registration Number
- CTRI/2018/10/016023
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All age groups patients with drug refractory epilepsy admitted in epilepsy monitoring unit for Video EEG , AIIMS New Delhi
Exclusion Criteria
1.Patients with chronic kidney and liver disease
2.Patients with shock, hypotension and known respiratory illness.
3. Acute precipitant of seizure was major trauma, hypoglycemia, cardiac arrest or heart rate less than 40 beats per minute.
4.Pregnant patients
5.Patients known allergic to midazolam.
6. Patients with known Coagulopathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean time in minutes/seconds required to terminate clinical and electrical seizure activity as documented by video EEG after drug administrationTimepoint: Patients having focal seizures for duration more than 5 minutes or generalized seizures more than 2 minutes will be given intranasal or intravenous midazolam as per randomization in following mentioned dose
- Secondary Outcome Measures
Name Time Method 1.Serious adverse events related to midazolam. <br/ ><br>2. Local side effects related to drug route . <br/ ><br>3. Any injury related to seizuresTimepoint: â?¢Patients having focal seizures for duration more than 5 minutes or generalized seizures more than 2 minutes will be given intranasal or intravenous midazolam as per randomization in following mentioned dose